GlassScriptPhysician profile
Michael Hartley Freeman
NPI 1700318441
$799.90
in general payments reported to CMS, 2019-2025
9 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Otology & Neurotology provider received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $78.80 · 2024: $329 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $224.79 | 2024-2025 | Dupixent |
| Med-El Corporation | $203.47 | 2024 | Mi1250 Synchrony 2 Flexsoft, Bci 602 Kit, Adhear Professional Kit |
| Genzyme Corporation | $107.31 | 2024-2025 | |
| Advanced Bionics, LLC | $91.31 | 2025 | Hires Ultra Ci Hifocus Ms Electrode |
| Ars Pharmaceuticals Operations, INC. | $24.30 | 2025 | Neffy |
| Cochlear Americas | $20.81 | 2024 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Astrazeneca Pharmaceuticals LP | $18.66 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $17.26 | 2025 | Elaprase |
| Optinose US, INC. | $13.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.